Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.2.2.7 (
heparinase
)
1,270
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The S100 family proteins
MRP-8
(S100A8) and MRP-14 (S100A9) form a heterodimer that is abundantly expressed in neutrophils, monocytes, and some secretory epithelia. In inflamed tissues, the
MRP-8
/14 complex is deposited onto the endothelium of venules associated with extravasating leukocytes. To explore the receptor interactions of
MRP-8
/14, we use a model system in which the purified
MRP-8
/14 complex binds to the cell surface of an endothelial cell line, HMEC-1. This interaction is mediated by the MRP-14 subunit and is mirrored by recombinant MRP-14 alone. The cell surface binding of MRP-14 was blocked by heparin, heparan sulfate, and chondroitin sulfate B, and the binding sites were sensitive to
heparinase
I and trypsin treatment but not to chondroitinase ABC. Furthermore
MRP-8
/14 and MRP-14 did not bind to a glycosaminoglycan-minus cell line. MRP-14 has a high affinity for heparin (K(d) = 6.1 +/- 3.4 nm), and this interaction mimicked that with the endothelial cells. We therefore conclude that the
MRP-8
/14 complex binds to endothelial cells via the MRP-14 subunit interacting chiefly with heparan sulfate proteoglycans. CD36 and RAGE, two other putative receptors for
MRP-8
/14, were not expressed by HMEC-1 cells. This binding activity may explain the immobilization of the
MRP-8
/14 complex on endothelium that is observed in vivo.
...
PMID:The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. 1172 10
S100A8
/A9 (calprotectin), which is released by neutrophils under inflammatory conditions, has the capacity to induce apoptosis in various cells. We previously reported that
S100A8
/A9 induces apoptosis of EL-4 lymphoma cells via the uptake of extracellular zinc in a manner similar to DTPA, a membrane-impermeable zinc chelator. In this study,
S100A8
/A9-induced apoptosis was examined in several cell lines that are weakly sensitive to DTPA, suggesting
S100A8
/A9 is directly responsible for apoptosis in these cells. Since zinc inhibits apoptosis of MM46, one of these cells, the regulation by zinc of the capacity of
S100A8
/A9 to bind MM46 cells was studied. When MM46 cells were incubated with
S100A8
/A9 in standard or zinc-depleted medium, the amounts of
S100A8
/A9 bound to cells was markedly lower at 3 h than at 1 h. In contrast, when MM46 cells were incubated with
S100A8
/A9 in the presence of high levels of zinc, binding to cells was the same at 1 and 3 h. When the cells were permeabilized with saponin prior to analysis, a larger amount of cell-associated
S100A8
/A9 was detected at 3 h. The amount was further increased in cells treated with chloroquine, suggesting that
S100A8
/A9 was internalized and degraded in lysosomes. Although it has been reported that
S100A8
/A9 binds to heparan sulfate on cell membranes, the amount of
S100A8
/A9 bound to MM46 cells was not reduced by
heparinase
treatment, but was reduced by trypsin treatment. These results suggest that
S100A8
/A9 induces apoptosis by direct binding to MM46 cells, and that this activity is regulated by zinc.
...
PMID:Regulation of S100A8/A9 (calprotectin) binding to tumor cells by zinc ion and its implication for apoptosis-inducing activity. 1625 95